About this trial
This is a randomized, double-blind, double arm study involving 128 participants who will undergo a total participation period of 12 weeks.
Eligibility criteria
Qualifiers
Providing written informed consent
Males and females of at least 18 years old
Body mass index (BMI) between 25 and 30 (including 25 and 30) (Weight: 25 < BMI < 30)
Having undergone treatment with GLP-1 for more than 3 months but for less than 1 year.
Disqualifiers
Being on GLP-1 treatment
Having had any type of bariatric surgery, or planned bariatric surgery during the period of trial participation.
Suffering from a severe chronic disease (e.g., cancer, HIV, hepatic or renal impairment, diabetes type I), inflammatory bowel disease (IBD), Coeliac Disease, and/or being immunocompromised.
Suffering from any uncontrolled endocrine disorder.
Trial design
Treatments tested in this trial
- UltraFlora® Triplebiotic
- Placebo